Pasadena Star News

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

November 16, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Why CRISPR Therapeutics Stock Could Be About to Take Off ↗

November 08, 2023

CRISPR's financial prospects could soon get an upgrade.

Gene correction technology took a big step forward this week.

Why CRISPR Therapeutics Stock Charged Northward This Week ↗

November 03, 2023

Forever stocks are usually those predicting future trends. Finding them today means pinning down strong financials and prospects without FOMO.

Invest in the Future With These 7 Forever Stocks ↗

November 15, 2023

Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.

3 Biotech Stocks With Key Catalysts Coming in December ↗

November 15, 2023

These stocks look reasonably priced today considering their long-term prospects.

2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher ↗

November 14, 2023

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday after Morgan Stanley maintained the company with an Underweight rating and lowered the price target. What To Know:

Topics Stocks

What's Going On With CRISPR Therapeutics Stock? ↗

November 13, 2023

Via Benzinga

3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024 ↗

November 12, 2023

Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year.

This company has been in the news for much of the year.

1 No-Brainer Stock to Buy and Hold for 10 Years ↗

November 11, 2023

Investors shouldn't have to deliberate for too long about these great stocks.

3 Growth Stocks to Buy Right Now Without Any Hesitation ↗

November 11, 2023

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗

November 10, 2023

The major indexes ended long win streaks. Datadog led earnings winners.

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues ↗

November 09, 2023

Vertex shares look cheap today considering all the company has to offer.

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

3 Biotech Stocks With the Strongest Clinical Pipelines ↗

November 08, 2023

On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗

November 08, 2023

Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely

Why you can make Vertex Pharmaceuticals a buy on any pullback

November 08, 2023

Via MarketBeat

Why CRISPR Therapeutics Stock Crushed the Market Today ↗

November 07, 2023

Investors were cheered by the company's latest earnings release, coupled with operational updates.

Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus ↗

November 07, 2023

The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments.

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

CRISPR Therapeutics AG (NYSE: CRSP) shares are trading higher Monday after the company announced preclinical data for its investigational programs for the

Why CRISPR Therapeutics Stock Is Moving Higher Monday ↗

November 06, 2023

Via Benzinga

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗

November 05, 2023

These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA ↗

November 03, 2023

The meeting went almost as well as could be expected.

Get these stocks while they're cheap.

3 Healthcare Stocks to Buy Hand Over Fist in November ↗

November 03, 2023

This stock could be a long-term winner, thanks to its game-changing technology.

One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? ↗

November 02, 2023

Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates.

Why Are Stocks Up Today? ↗

November 01, 2023

Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie.

Topics Economy

Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? ↗

November 01, 2023

The agency could soon approve a potential cure for sickle cell disease .

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug ↗

November 01, 2023